Get the Stockscreener App
6.68
6.03%
0.38
After Hours:
6.80
0.12
+1.80%
Cybin Inc stock is traded at $6.68, with a volume of 880.38K.
It is up +6.03% in the last 24 hours and up +3.41% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$6.30
Open:
$6.35
24h Volume:
880.38K
Relative Volume:
1.10
Market Cap:
$333.29M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-32.16
EPS:
-0.2077
Net Cash Flow:
$-44.93M
1W Performance:
+11.52%
1M Performance:
+3.41%
6M Performance:
-22.77%
1Y Performance:
-33.47%
1-Day Range:
$6.35
$6.84
1-Week Range:
$5.61
$6.84
52-Week Range:
$4.81
$10.73
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Compare CYBN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
6.68 | 314.33M | 0 | -52.07M | -44.93M | -0.2077 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin (OTCMKTS:CYBN) Trading 5.5% HigherShould You Buy? - MarketBeat
What drives Cybin Inc stock priceQuarterly Earnings Review & Small Budget Investment Growth - earlytimes.in
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
Cybin taps Thermo Fisher for U.S. manufacturing of CYB003 - MSN
Cybin (OTCMKTS:CLXPF) Shares Up 5.7%Time to Buy? - MarketBeat
Earnings Beat: Why Cybin Inc stock could be next big winnerMarket Risk Summary & Low Volatility Stock Suggestions - BỘ NỘI VỤ
Will Cybin Inc. stock benefit from automationEarnings Beat & High Accuracy Swing Trade Signals - Newser
Will Cybin Inc. (R7E) stock outperform value peersStop Loss & Stepwise Swing Trade Plans - Newser
Is Cybin Inc. (R7E) stock a good hedge against inflation2025 Performance Recap & AI Driven Stock Reports - Newser
Cybin (NYSEAMERICAN:CYBN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
Can Cybin Inc. (R7E) stock attract ESG investmentsTrade Risk Summary & Reliable Entry Point Trade Alerts - Newser
How geopolitical risks impact Cybin Inc. (R7E) stockJuly 2025 Rallies & Real-Time Volume Analysis - Newser
Cybin price target raised to $48 from $39 at Guggenheim - MSN
Is Cybin Inc. stock overvalued by current metricsJuly 2025 Big Picture & Weekly Market Pulse Updates - Newser
Guggenheim Maintains Cybin (CYBN) Buy Recommendation - Nasdaq
Guggenheim Raises Price Target for Cybin (CYBN) to $48.00 | CYBN Stock News - GuruFocus
Guggenheim raises Cybin stock price target to $48 on clinical progress - Investing.com Australia
Guggenheim raises Cybin stock price target to $48 on clinical progress By Investing.com - Investing.com South Africa
Can Cybin Inc. Common Shares stock sustain free cash flowQuarterly Risk Review & Daily Oversold Bounce Ideas - Newser
Cybin (NYSEAMERICAN:CYBN) Trading Down 8.2%Here's Why - MarketBeat
Will Cybin Inc. Common Shares stock test record highs in 2025Earnings Trend Report & Weekly Stock Breakout Alerts - Newser
Why Cybin Inc. Common Shares stock could be top winnerTrade Risk Summary & Real-Time Chart Pattern Alerts - Newser
Cybin price target lowered to $55 from $150 at H.C. Wainwright - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Cybin Inc. (CYBN) S - The National Law Review
Why Cybin Inc. stock could be next big winnerQuarterly Profit Report & Accurate Entry and Exit Point Alerts - BỘ NỘI VỤ
Cybin Announces Up to USD$35 Million At-The-Market Equity Program - Investing News Network
Cybin Secures $175 Million in Direct Offering to Advance Clinical Programs - MSN
[6-K] CYBIN INC. Current Report (Foreign Issuer) | CYBN SEC FilingForm 6-K - Stock Titan
Understanding Momentum Shifts in (CYBN) - news.stocktradersdaily.com
Will Cybin Inc. stock gain from government policiesJuly 2025 EndofMonth & Weekly Top Gainers Alerts - newser.com
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges By GuruFocus - Investing.com Canada
Cybin Inc (CYBN) Q2 2026 Earnings Call Highlights: Strategic Advancements Amid Financial Challenges - GuruFocus
Canaccord Genuity Maintains Cybin (CYBN) Buy Recommendation - Nasdaq
Cybin (CYBN) Analyst Rating Update: Canaccord Genuity Lowers PT to $45 | CYBN Stock News - GuruFocus
Canaccord Genuity lowers Cybin stock price target to $45 on dilution - Investing.com Australia
Canaccord Genuity lowers Cybin stock price target to $45 on dilution By Investing.com - Investing.com South Africa
Cybin price target lowered to $45 from $70 at Canaccord - TipRanks
Can Cybin Inc. stock deliver surprise earnings beatQuarterly Performance Summary & Precise Swing Trade Alerts - newser.com
What’s the recovery path for long term holders of Cybin Inc.Index Update & Consistent Growth Equity Picks - newser.com
Why Cybin Inc. Common Shares stock is a strong analyst pickEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Is Cybin Inc. Common Shares stock positioned for digital growth eraJuly 2025 Analyst Calls & Proven Capital Preservation Methods - newser.com
What market sentiment indicators show for Cybin Inc. Common Shares stockTrade Risk Assessment & Low Volatility Stock Suggestions - newser.com
How reliable is Cybin Inc. (R7E) stock dividend growthGap Down & Long-Term Capital Growth Strategies - newser.com
Will Cybin Inc. Common Shares stock remain on Wall Street radarJuly 2025 Drop Watch & Low Drawdown Investment Strategies - newser.com
Will Cybin Inc. stock gain from strong economyStop Loss & Expert Verified Movement Alerts - newser.com
Price momentum metrics for Cybin Inc. explainedJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How higher bond yields impact Cybin Inc. (R7E) stockJuly 2025 Short Interest & Entry Point Confirmation Alerts - newser.com
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Cap:
|
Volume (24h):